Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion A/S reports developments as a clinical-stage TechBio company using its proprietary AI-Immunology™ platform to design vaccine candidates for cancer and infectious diseases. Company news commonly covers EVX-01, its personalized peptide-based cancer vaccine for advanced solid cancers, including data from a phase 2 advanced melanoma trial and measures of neoantigen target selection and immune response.
Updates also address platform applications beyond melanoma, including glioblastoma vaccine design, prophylactic infectious disease concepts such as polio and cytomegalovirus programs, collaborations, business development activity, quarterly financial results, annual general meeting outcomes, board matters, and management-role changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Evaxion Biotech A/S (NASDAQ: EVAX) announced significant progress in its clinical trials and technology advancements during a recent financial update. The Company presented promising data from the Phase 1/2a trial of EVX-02 at the AACR 2023, showing all 10 patients remained relapse-free after a year. EVX-03, a personalized cancer vaccine, is set to begin a Phase 1 trial in Q4 2023 following a CTA filing expected in Q3 2023. The Company has enhanced its AI capabilities with the new ObsERV™ technology, which targets viral antigens in tumors. Financially, Evaxion reported $13 million in cash as of December 31, 2022, sufficient to fund operations until December 2023. They acknowledged previous net losses but highlighted reduced R&D spending. They plan to provide further updates on their trials and pipeline in 2023.
Evaxion Biotech reported promising results from its Phase 1/2a clinical trial of EVX-02, a personalized cancer immunotherapy, presented at the 2023 AACR meeting. All 10 late-stage melanoma patients who completed treatment showed robust immune responses and remained relapse-free at their last assessment. The study, which combined EVX-02 with the checkpoint inhibitor nivolumab, demonstrated safety and tolerability, with only mild adverse events noted. The outcomes support the predictive capabilities of Evaxion's AI technology and pave the way for the development of EVX-03, expected to enter the clinic in Q4 2023.
Evaxion Biotech A/S (NASDAQ: EVAX) has published promising preclinical data in Frontiers of Immunology regarding its AI-driven viral vaccine discovery platform, RAVEN. Conducted with Pennsylvania State University, this study highlights the platform's ability to identify protective T-cell epitopes from SARS-CoV-2 in a COVID-19 mouse model, effectively preventing severe disease and mortality. The RAVEN platform is positioned to streamline vaccine development against a variety of viral diseases, with potential implications for enhancing both existing and new vaccines. Chief Scientific Officer Birgitte Rønø emphasized the significance of this research in tailoring vaccines for broad population protection. The study marks a pivotal point as the first instance of an AI-designed T-cell vaccine demonstrating in vivo protection against severe COVID-19, potentially paving the way for rapid responses to emerging viral threats.